Conclusion:
This study of the first 20 patients prescribed selexipag in our centre demonstrates that selexipag can be safely initiated, titrated and transitioned in an outpatient setting to achieve an individualised dosing regimen. Prostacyclin side effects were common, but improved in the maintenance phase. There were no drug discontinuations or deaths in this study, but close observation and consideration of clinical, biochemical and hemodynamic parameters are recommended following any changes in drug therapy.
References :
1. Lang IM and Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev 2015; 24: 630-641. 2015/12/02. DOI: 10.1183/16000617.0067-2015.
2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). The European respiratory journal 2015; 46: 903-975. 2015/09/01. DOI: 10.1183/13993003.01032-2015.
3. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H1235-H1248. 2010/01/15. DOI: 10.1152/ajpheart.00254.2009.
4. Menyhart K and Nayler O. Influence of IP Receptor Density on Agonist Activity of ACT-333679, the Active Metabolite of Selexipag. A66 PH: MOLECULES, CELLS AND ANIMAL MODELS . pp.A2239-A2239.
5. Farber HW and Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway.European Respiratory Review 2016; 25: 418-430. DOI: 10.1183/16000617.0083-2016.
6. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension.New England Journal of Medicine 2015; 373: 2522-2533. DOI: 10.1056/NEJMoa1503184.
7. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal 2012; 40: 874-880. DOI: 10.1183/09031936.00137511.
8. Gomberg-Maitland M and Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 2008; 31: 891-901. DOI: 10.1183/09031936.00097107.
9. Surveillance for respiratory hazards in the occupational setting [American Thoracic Society].Am Rev Respir Dis 1982; 126: 952-956. 1982/11/01.
10. Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ 2017; 7: 598-608. 2017/07/11. DOI: 10.1177/2045893217719250.
11. Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine 2015; 373: 834-844. DOI: 10.1056/NEJMoa1413687.
12. Sitbon O and Gaine S. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.European Respiratory Review 2016; 25: 408-417. DOI: 10.1183/16000617.0085-2016.
13. Sofer A, Ryan MJ, Tedford RJ, et al. A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulm Circ 2017; 7: 326-338. 2017/06/10. DOI: 10.1177/2045893217706357.
14. Chakinala MM, Feldman JP, Rischard F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant 2017; 36: 193-201. 2016/07/30. DOI: 10.1016/j.healun.2016.06.019.
15. Frost A, Janmohamed M, Fritz JS, et al. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant 2019; 38: 43-50. 2018/11/06. DOI: 10.1016/j.healun.2018.09.003.
16. Yanaka K, Guillien A, Soumagne T, et al. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. European Respiratory Journal 2020; 55: 1902418. DOI: 10.1183/13993003.02418-2019.
17. Pan IZ, Carey JR, Jacobs JA, et al. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. Front Med (Lausanne) 2020; 7: 81-81. DOI: 10.3389/fmed.2020.00081.
18. Bhura S and Gibbons W. TRANSITIONING FROM INHALED ILOPROST TO ORAL SELEXIPAG: A CASE REPORT.Chest 2019; 156: A741. DOI: 10.1016/j.chest.2019.08.714.
19. Olschewski H, Simonneau G, Galiè N, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine 2002; 347: 322-329. DOI: 10.1056/NEJMoa020204.
20. Nakayama K, Emoto N, Tamada N, et al. The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension. Pulm Circ 2018; 8: 2045894018781537-2045894018781537. 2018/05/21. DOI: 10.1177/2045894018781537.
21. Gaine S, Sitbon O, Channick RN, et al. The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension. A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH . pp.A2502-A2502.
22. Holthaus N, Prins K, Rose L, et al. EXPRESS: Transition from Parental Prostacyclin to Selexipag: A Case Series of Five Pulmonary Arterial Hypertension Patients. Pulm Circ 2019: 2045894019862167. 2019/06/20. DOI: 10.1177/2045894019862167.
23. McLaughlin VV, Channick R, De Marco T, et al. Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest 2020; 157: 955-965. 2019/11/19. DOI: 10.1016/j.chest.2019.10.043.
24. Hardin EA and Chin KM. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Drug Des Devel Ther 2016; 10: 3747-3754. DOI: 10.2147/DDDT.S103534.
25. Gatfield J, Menyhart K, Wanner D, et al. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential. J Pharmacol Exp Ther2017; 362: 186-199. 2017/05/10. DOI: 10.1124/jpet.116.239665.